Saidal Group is a prominent Algerian public pharmaceutical company, established in 1982. It plays a crucial role in the nation's healthcare sector by manufacturing, developing, and marketing a wide range of essential generic medicines, aiming to ensure national drug sovereignty and reduce import dependency.

Manufacturing and Product Portfolio

Saidal Group operates multiple production units across Algeria, specializing in the manufacturing of generic drugs for various therapeutic areas. Its portfolio includes medicines for cardiology, diabetes, anti-infectives, and CNS disorders. The company adheres to international quality standards, including Good Manufacturing Practices (GMP), ensuring product efficacy and safety. Saidal continually invests in modernizing facilities and expanding capacity to meet the growing demand for affordable healthcare solutions in Algeria and for export.

Research, Development, and National Impact

Beyond manufacturing, Saidal Group engages in research and development initiatives to localize drug production and foster innovation. It collaborates with academic institutions and healthcare professionals to enhance its offerings and address public health needs. As a key public enterprise, Saidal Group is a cornerstone of Algeria's pharmaceutical industry, contributing significantly to job creation and the national economy, while improving access to essential medicines for the Algerian population.